Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat‐fed, streptozotocin‐treated diabetic rats
Open Access
- 1 September 2005
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 146 (2) , 234-243
- https://doi.org/10.1038/sj.bjp.0706306
Abstract
Protein tyrosine phosphatase 1B (PTP1B) acts as a physiological negative regulator of insulin signaling by dephosphorylating the activated insulin receptor (IR). Here we examine the role of PTP1B in the insulin‐sensitizing action of rosiglitazone (RSG) in skeletal muscle and liver. Fat‐fed, streptozotocin‐treated rats (10‐week‐old), an animal model of type II diabetes, and age‐matched, nondiabetic controls were treated with RSG (10 μmol kg−1 day−1) for 2 weeks. After RSG treatment, the diabetic rats showed a significant decrease in blood glucose and improved insulin sensitivity. Diabetic rats showed significantly increased levels and activities of PTP1B in the skeletal muscle (1.6‐ and 2‐fold, respectively) and liver (1.7‐ and 1.8‐fold, respectively), thus diminishing insulin signaling in the target tissues. We found that the decreases in insulin‐stimulated glucose uptake (55%), tyrosine phosphorylation of IRβ‐subunits (48%), and IR substrate‐1 (IRS‐1) (39%) in muscles of diabetic rats were normalized after RSG treatment. These effects were associated with 34 and 30% decreases in increased PTP1B levels and activities, respectively, in skeletal muscles of diabetic rats. In contrast, RSG did not affect the increased PTP1B levels and activities or the already reduced insulin‐stimulated glycogen synthesis and tyrosine phosphorylation of IRβ‐subunits and IRS‐2 in livers of diabetic rats. RSG treatment in normal rats did not significantly change PTP1B activities and levels or protein levels of IRβ, IRS‐1, and ‐2 in diabetic rats. These data suggest that RSG enhances insulin activity in skeletal muscle of diabetic rats possibly by ameliorating abnormal levels and activities of PTP1B. British Journal of Pharmacology (2005) 146, 234–243. doi:10.1038/sj.bjp.0706306Keywords
This publication has 57 references indexed in Scilit:
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Effect of Contraction on Mitogen-activated Protein Kinase Signal Transduction in Skeletal MuscleJournal of Biological Chemistry, 2000
- Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.Diabetes Care, 2000
- Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilutionBritish Journal of Pharmacology, 1999
- Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolismBritish Journal of Pharmacology, 1999
- Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetesJournal of Clinical Investigation, 1999
- Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide YBritish Journal of Pharmacology, 1997
- Evidence for a Role of Glucose-induced Translocation of Glucokinase in the Control of Hepatic Glycogen SynthesisJournal of Biological Chemistry, 1996
- Protein‐Tyrosine phosphatases and the regulation of insulin actionJournal of Cellular Biochemistry, 1992
- The significance and interpretation of mildly abnormal oral glucose toleranceDiabetologia, 1971